BOJI CRO(300404)2020-08-27 16:00Financial Performance - The company's operating revenue for the first half of 2020 was CNY 110,045,597.78, representing a 17.93% increase compared to CNY 93,316,182.27 in the same period last year[18]. - The net profit attributable to shareholders of the listed company reached CNY 11,874,953.42, a significant increase of 303.23% from CNY 2,944,975.71 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 8,991,567.52, up 581.16% from CNY 1,320,038.74 in the same period last year[18]. - The net cash flow from operating activities was CNY 44,226,652.47, an increase of 526.31% compared to CNY 7,061,413.83 in the previous year[18]. - Basic earnings per share increased to CNY 0.0526, a rise of 301.53% from CNY 0.0131 in the previous year[18]. - Total operating revenue for the first half of 2020 reached ¥110,045,597.78, an increase of 17.9% compared to ¥93,316,182.27 in the first half of 2019[153]. - Net profit for the first half of 2020 was ¥14,866,119.67, a significant increase of 354.5% from ¥3,272,443.07 in the same period last year[155]. - The total comprehensive income for the first half of 2020 was ¥15,080,552.18, compared to ¥3,299,938.46 in the same period last year, reflecting a growth of 356.5%[156]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 712,113,224.44, reflecting a 12.48% increase from CNY 633,081,946.60 at the end of the previous year[18]. - The total liabilities increased to CNY 229,731,499.54 from CNY 177,003,294.01, indicating a rise of approximately 29.8%[147]. - The company's total assets at the end of the first half of 2020 were CNY 450.88 million, compared to CNY 422.84 million at the end of the previous year[174]. - The total liabilities at the end of the period were approximately 6,957 million yuan, indicating a manageable debt level[170]. Cash Flow - The net cash flow from operating activities for the first half of 2020 was CNY 44,226,652.47, a significant increase from CNY 7,061,413.83 in the same period of 2019, representing a growth of approximately 527%[162]. - Cash inflow from financing activities totaled CNY 49,966,715.62, a substantial increase from CNY 1,356,628.50 in the first half of 2019[163]. - The ending balance of cash and cash equivalents increased to CNY 96,276,582.68 from CNY 69,841,125.50, representing a growth of about 37.9%[163]. Research and Development - The company is focusing on the development of new drugs and generics, leveraging its technical expertise and industry experience[27]. - The company has provided clinical research services for over 800 projects, helping clients obtain more than 60 new drug certificates and approximately 80 production approvals[36]. - The company’s R&D investment increased by 46.37% to ¥10,737,338.09, indicating a strong commitment to innovation[52]. - The company has established five major R&D service platforms, significantly enhancing its capabilities in preclinical research services[40]. Market Position and Strategy - The company operates as a professional CRO service provider, offering a full range of services including preclinical research, clinical research, and CDMO services[25]. - The global CRO market size reached 95.1 billion[29]. - The domestic CRO market size was approximately 21.4 billion[30]. - The company is one of the few CROs in China capable of providing full-process "one-stop" services for new drug development[34]. Governance and Compliance - All directors attended the board meeting to review this report, ensuring comprehensive oversight[4]. - The financial report was approved by the board of directors on August 26, 2020[182]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[68][69]. Risks and Challenges - The company faces risks related to policy changes in the new drug research industry, which could impact its business operations and revenue[73]. - The company is facing increased market competition due to the rapid growth of domestic CRO companies, which necessitates improved marketing and service levels[75]. - The company has implemented measures to mitigate risks associated with long-term contract execution in new drug development[74]. Shareholder Information - The number of shareholders holding more than 5% of ordinary shares includes Wang Tingchun with 35.57% and Zhao Lingli with 8.87%[125]. - The total number of ordinary shareholders at the end of the reporting period was 10,096[125]. - The company has implemented a stock option incentive plan, with the first exercise period completed in 2019[120]. Miscellaneous - The company has not engaged in any poverty alleviation initiatives during the reporting period and has no plans for future initiatives[107]. - The company has not conducted any major litigation or arbitration matters during the reporting period[85]. - The company has not received any penalties or corrective actions during the reporting period[87].